A5011507616- Hepatocellular Carcinoma Treatment and Prognosis
- Pancreatic and Hepatic Oncology Research
- Neuroendocrine Tumor Research Advances
- Liver Disease Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Hepatitis B Virus Studies
- Hepatitis C virus research
- Cancer Mechanisms and Therapy
- Lung Cancer Research Studies
- Pancreatitis Pathology and Treatment
- HIV/AIDS drug development and treatment
- Reproductive System and Pregnancy
- Endometriosis Research and Treatment
- Ferroptosis and cancer prognosis
- Liver physiology and pathology
- Renal cell carcinoma treatment
- Ovarian function and disorders
- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Reproductive Biology and Fertility
- Gastrointestinal disorders and treatments
- Body Composition Measurement Techniques
- Cancer therapeutics and mechanisms
- Liver Disease and Transplantation
- Esophageal and GI Pathology
Kanagawa Prefectural Hospital Organization
2018-2025
Kanagawa Cancer Center
2018-2025
Yokohama City University
2021
Yokohama Minami Kyosai Hospital
2017-2019
Toranomon Hospital
2012-2016
Kumamoto University
1982-1983
Immune checkpoint inhibitors (ICIs) are effective for advanced hepatocellular carcinoma (HCC). However, there few reports on the correlation between clinical efficacy of ICIs and development immune-related adverse events (irAEs) in patients with HCC. The aim this study was to investigate association irAE survival HCC treated atezolizumab plus bevacizumab.We enrolled 150 bevacizumab October 2020 2021 at 5 territorial institutions. We compared who experienced irAEs (irAE group) those did not...
To assess the safety, efficacy and prognostic impact of clinical factors related to lenvatinib treatment in Child-Pugh class A (CP-A) B (CP-B) patients with unresectable hepatocellular carcinoma (u-HCC).Patients u-HCC who were treated at multiple centers Japan retrospectively analyzed for outcomes according their respective CP status. Radiological objective response (OR) was assessed using modified evaluation criteria solid tumors (mRECIST) guidelines.Baseline demographic parameters...
To assess the impact of clinical factors on safety and efficacy atezolizumab plus bevacizumab (ATZ + BV) treatment in patients with unresectable hepatocellular carcinoma (u-HCC).Ninety-four u-HCC who were treated ATZ BV at multiple centers enrolled. We defined Child-Pugh (CP)-A received as a first line therapy 'meets broad sense IMbrave150 criteria' group (B-IMbrave150-in, n = 46), later or CP-B (regardless whether was therapy) B-IMbrave150-out (n 48). Patients retrospectively analyzed for...
737 Background: There were some reports that nal-IRI + 5FU/LV (NAPOLI) therapy was effective for patients with unresectable pancreatic cancer who had a history of treatment containing conventional irinotecan (IRI) though the others did not. We aimed to investigate factors contribute effectiveness NAPOLI have already received IRI-containing treatment. Methods: retrospectively enrolled consecutive previously treated and started at our hospital between June 2020 December 2022. compared patient...
Abstract Pancreatic cancer frequently involves cancer‐associated thromboembolism, which is strongly associated with poor prognosis. Tissue factor, a blood coagulation factor largely produced in patients as component of extracellular vesicles, plays key role the incidence thromboembolism pancreatic cancer. However, no prospective studies have been published on relationship between tissue and or patient clinical characteristics, including recent chemotherapy regimens. Thus, we aimed to address...
Aims To assess the safety, efficacy, and prognostic impact of clinical factors associated with lenvatinib treatment in highly advanced hepatocellular carcinoma (HCC) tumor thrombus main portal vein trunk (VP4) or more than 50% liver occupation (tm50%LO). Methods A total 61 HCC patients (41 tm50%LO 20 VP4) who were treated at multicenter enrolled retrospectively analyzed for outcomes according to their status, including morphology. Results The most frequent grade ≥3 adverse event was elevated...
The aim of the study was to clarify association skeletal muscle mass and prognosis unresectable pancreatic ductal adenocarcinoma (PDAC) treated with gemcitabine plus nab-paclitaxel (GnP).We included 124 PDAC patients who received GnP chemotherapy. Skeletal third lumbar vertebrae (L3) level measured by computed tomography immediately before initiation, index (L3-SMI) calculated. Sarcopenia defined as L3-SMI less than 42 cm2/m2 in male 38 female patients.Sarcopenia found 63 (50.8%). There no...
The preferred regimen for unresectable pancreatic cancer following gemcitabine-based chemotherapy is not well-established. This study compared the efficacy of (ⅰ) liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU)/leucovorin (LV) (nal-IRI/5-FU/LV) versus modified FOLFIRINOX (mFFX) and (ⅱ) nal-IRI/5-FU/LV FOLFIRI, respectively, safety three regimens each other, as second-line chemotherapies cancer.This was a retrospective single-center analysis all patients who were administered...
Objectives This study aimed to assess the lesser known therapeutic benefit, particularly safety and effectiveness of gemcitabine plus nab-paclitaxel (GnP) treatment in elderly patients with advanced pancreatic cancer. Methods We retrospectively enrolled cancer aged ≥75 years who received GnP as first-line between December 2014 2016. assessed survival, adverse events, early discontinuation. Results The cohort comprised 116 (median age, 77 [range, 75–84] years). overall survival...
Aim Tolvaptan, an oral arginine vasopressin V 2 receptor antagonist, became available for hepatic ascites. We evaluated the therapeutic efficacy and safety of tolvaptan administration to treat refractory Methods Data were collected from 15 hospitalized patients with cirrhosis (hepatitis C , 10; alcoholism, five) after adding (3.75–11.25 mg/day) conventional diuretics. Bodyweights serum sodium creatinine concentrations measured. Tolvaptan was continued 4 weeks or longer a median follow‐up...
It is often difficult to predict the response telaprevir-pegylated interferon (PEG-IFN)-ribavirin triple therapy and appearance of telaprevir-resistant variants. The present study determined predictive factors a sustained virological (SVR) 12- or 24-week (T12PR12 T12PR24, respectively) in 194 Japanese patients infected with hepatitis C virus genotype 1b (HCV-1b). also evaluated whether ultradeep sequencing technology can at baseline emergence resistant variants after start therapy. Analysis...
Abstract Background Fluorouracil, leucovorin (5FU/LV), and nanoliposomal-irinotecan (nal-IRI) combination therapy has been established as the second-line treatment for advanced pancreatic ductal adenocarcinoma. Oxaliplatin with 5FU/LV (FOLFOX) is often used a subsequent treatment, although its efficacy safety are yet to be fully elucidated. We aimed evaluate of FOLFOX third- or later-line patients Methods conducted single-centre, retrospective study that enrolled 43 who received after...
Aim Patients with unresectable hepatocellular carcinoma ( HCC ) often undergo transcatheter arterial chemoembolization TACE ). Miriplatin is a lipophilic cisplatin derivative used in that effective . However, the difference antitumor efficacy between warmed versus room temperature miriplatin unclear. Methods Chemotherapy was evaluated by dynamic computed tomography 1–3 months after , according to M odified R esponse E valuation C riteria S olid T umors. A total of 203 patients who received...
<b><i>Objectives:</i></b> A randomized controlled trial was conducted to evaluate the efficacy of impedance control a radiofrequency interstitial thermal ablation system (RITA) used treat hepatocellular carcinoma (HCC). <b><i>Methods:</i></b> Fifteen patients with hypervascular HCCs <20 mm in diameter were randomly treated (RFA) using conventional temperature (group A) or methods B). RITA needle electrodes all cases. We compared time, extent...
A group of 22 women with anovulatory cycles was treated tamoxifen in 46 cycles. We elucidated daily hormone profiles 5 the 33 tamoxifen-induced ovulatory order to make a comparison those found normal Serum follicle-stimulating and luteinizing (LH) rose during or few days after therapy, thereafter serum estradiol levels gradually over ranges follicular phase reached an extremely high preovulatory peak which triggered LH surge. This increased production exerted its usual negative feedback on...
Treatment of hepatocellular carcinoma located on the liver surface is frequently difficult because direct puncture tumor must be avoided during needle insertion. The aim this study was to investigate utility a no-touch pincer ablation procedure that uses multipolar radiofrequency (RFA) system for surface.The experimental animals were three pigs, and RFA performed with two internally cooled bipolar electrodes. Three ablative procedures compared: linear insertion at regular 13-mm intervals...
Genome-wide association studies (GWAS) recently indicated that polymorphisms in the human leucocyte antigen (HLA)-DP genes were associated with risk of persistent hepatitis B virus (HBV) infection and clearance HBV, but effect HLA-DP gene on antiviral therapy was unknown. We here investigated whether such decreases HBsAg levels seroclearance patients who received long-term lamivudine (LAM) treatment.Japanese (202) e positive at baseline, LAM as first-line treatment, consented to genotyping...
The clinical usefulness of detecting telaprevir-resistant variants is unclear. Two hundred fifty-two Japanese patients infected with hepatitis C virus (HCV) genotype 1b received triple therapy telaprevir-peginterferon (PEG-IFN)-ribavirin and were evaluated for by direct sequencing at baseline the time reelevation viral load. An analysis entire group indicated that 76% achieved a sustained virological response. Multivariate identified PEG-IFN dose <1.3 μg/kg body weight, an IL28B rs8099917...
Abstract Background Transarterial chemoembolization (TACE) is the standard treatment for intermediate stage hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] B). However, it often leads to a poor prognosis and decreased hepatic function especially in patients with BCLC substage B2. Lenvatinib (LEN) was demonstrated be efficacious these REFLECT phase 3 trial. We therefore aimed evaluate efficacy safety of LEN as first-line HCC at Methods This prospective observational study...
Abstract Background Although the combination of atezolizumab and bevacizumab (ATZ + BEV) is a standard treatment for advanced hepatocellular carcinoma (HCC), strategies addressing failure prognostic factors post‐progression survival (PPS) remain unestablished. Methods We conducted multicentre retrospective study to evaluate PPS following ATZ BEV in patients with HCC. classified into three groups: BCLC stage B C without or new extrahepatic lesions (BCLCp‐C1 BCLCp‐C2, respectively) at time...
Cabozantinib is a multi-kinase inhibitor targeting multiple tyrosine kinases. It improves overall survival and progression-free in patients previously treated with sorafenib for advanced hepatocellular carcinoma (HCC) compared to the placebo phase 3 CELESTIAL trial. A 71-year-old man presented our hospital treatment of HCC chronic hepatitis C. He was refractory sorafenib, lenvatinib, regorafenib, ramucirumab started atezolizumab bevacizumab therapy November 2020. After administering second...